Cytovia Therapeutics, a biopharmaceutical company, went public via SPAC merger with Isleworth Healthcare Acquisition, a special purpose acquisition company. Financial terms were not disclosed. "Isleworth evaluated multiple life science companies and was most impressed by the talent and technology assembled by Cytovia. We believe Cytovia is one of the most advanced, innovative cell therapy companies involved with the development of new cancer treatments. Cell therapies in oncology have already brought hope to millions. Cytovia's approaches could conceivably make similar approaches more conveniently 'off-the-shelf' and affordable," Bob Whitehead, Isleworth CEO.